Literature DB >> 28885919

Diagnostics in a Forward Deployed Setting.

Brett Swierczewski1, Mark Simons2.   

Abstract

Current diagnostic methods for enteric pathogens include conventional/traditional microbiology, microscopy, enzyme immunoassay, automated identification platforms, and molecular methods. The choice of diagnostic test in the forward deployed military setting often depends on turnaround time, potential etiologic agents, costs, and laboratory capabilities. The military operational environment presents many challenges that impact the practicality and performance of even robust diagnostic platforms. With recent developments in diagnostic platforms and availability of high-performance multiplex molecular methods to pair with traditional culture and antibiotic susceptibility tests, there are more opportunities to gather information on the etiologic causes and clinical impacts of traveler's diarrhea, both in civilians and in deployed military populations. Nevertheless, further assessment of new test methods is warranted to determine field applicability in forward deployed military settings. Reprint &
Copyright © 2017 Association of Military Surgeons of the U.S.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28885919     DOI: 10.7205/MILMED-D-17-00069

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  Infectious diseases during the European Union training mission Mali (EUTM MLI) - a four-year experience.

Authors:  Hagen Frickmann; Ralf Matthias Hagen; Florian Geiselbrechtinger; Nagpal Hoysal
Journal:  Mil Med Res       Date:  2018-05-31

2.  A Multisite Network Assessment of the Epidemiology and Etiology of Acquired Diarrhea among U.S. Military and Western Travelers (Global Travelers' Diarrhea Study): A Principal Role of Norovirus among Travelers with Gastrointestinal Illness.

Authors:  Hayley R Ashbaugh; June M Early; Myles E Johnson; Mark P Simons; Paul C F Graf; Mark S Riddle; Brett E Swierczewski
Journal:  Am J Trop Med Hyg       Date:  2020-11       Impact factor: 2.345

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.